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Clinical Infectious Diseases
MAJOR ARTICLE

A Randomized Phase 2 Study of VT-1161 for the
Treatment of Acute Vulvovaginal Candidiasis
Stephen R. Brand,1,2,a Jack D. Sobel,3 Paul Nyirjesy,4,b Mahmoud A. Ghannoum,5 Robert J. Schotzinger,1,a and Thorsten P. Degenhardt1,2,a
1

Viamet Pharmaceuticals, Durham, North Carolina, USA, 2Mycovia Pharmaceuticals, Durham, North Carolina, USA, 3School of Medicine, Wayne State University, Detroit, Michigan, USA, 4Sidney
Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA, and 5Center for Medical Mycology, Case Western Reserve University, and University Hospitals Cleveland
Medical Center, Cleveland, Ohio, USA

Acute vulvovaginal candidiasis (VVC) is typically treated with
a single dose or short treatments of either topical or oral azole
antifungals, while recurrent VVC requires treatments that can
last ≥6 months [1, 2]. Fluconazole remains the current standard
of care; however, drug resistance and safety liabilities, including
hepatic toxicity, drug–drug interactions (DDIs), pregnancy warnings, and miscarriage concerns, are associated with its use [3–7].
VT-1161 (oteseconazole) was designed to be highly selective
for fungal CYP51, thus avoiding off-target toxicities, including
pregnancy and miscarriage concerns often associated with
the azole drug class [8]. Moreover, VT-1161 has demonstrated
greater potency against Candida species, including azole-resistant
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species, than fluconazole [9]. Our goal in this phase 2a study was
to evaluate the safety and efficacy of VT-1161 vs fluconazole in
the treatment of patients with moderate to severe acute VVC.
METHODS
Study Design

This was a phase 2, multicenter, randomized, double-blind,
active-controlled, parallel-group, dose-ranging trial designed
to evaluate the efficacy, safety, and pharmacokinetics (PK) of
3 dose levels of oral VT-1161 compared with a single dose of
fluconazole, the current US Food and Drug Administration–
approved regimen [10]. The study was conducted at 8 sites in
the United States between October 2013 and September 2014.
The available data suggested that VT-1161 plasma exposures
of 1–1.5 µg/mL should be clinically effective. This exposure
target was therefore chosen to guide the selection of the lowdose arm. Given the safety profile of VT-1161, the mid-dose arm
regimen would provide higher exposures (approximately 2-fold
greater than the low-dose arm) and would afford the assessment
of PK/pharmacodynamic relationships. The study design also
afforded the opportunity to escalate to a higher-dose arm.
Participants were randomly assigned to receive 1 of the following dose regimens (Figure 1): VT-1161 300 mg once daily
(q.d.) for 3 days (low dose), VT-1161 600 mg q.d. for 3 days
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Background. Acute vulvovaginal candidiasis (VVC) is common among women, but current azole antifungal treatments are often
associated with safety and resistance issues. VT-1161 (oteseconazole) is an oral agent with increased selectivity for fungal CYP51. In this
phase 2 clinical study, we evaluated the efficacy and safety of VT-1161 vs fluconazole in participants with moderate to severe acute VVC.
Methods. Participants presenting with an acute episode of VVC (n = 55) were randomized to receive VT-1161 300 mg once
daily (q.d.) for 3 days, 600 mg q.d. for 3 days, or 600 mg twice daily (b.i.d.) for 3 days or to receive a single dose of fluconazole 150 mg
(FDA-approved dose to treat acute VVC). Participants were followed for 6 months. The primary outcome was the proportion of participants with therapeutic (clinical and mycological) cure at day 28.
Results. A larger proportion of participants in the per-protocol population experienced therapeutic cure in the VT-1161 300 mg
q.d. (75.0%), VT-1161 600 mg q.d. (85.7%), and VT-1161 600 mg b.i.d. (78.6%) groups vs the fluconazole group (62.5%); differences
were not statistically significant. At 3 and 6 months, no participants in the VT-1161 groups vs 28.5% and 46.1% in the fluconazole
group, respectively, had evidence of mycological recurrence. No serious adverse events or treatment-emergent adverse events leading
to discontinuation were reported.
Conclusions. The majority of participants across all treatment groups achieved therapeutic cure at day 28. VT-1161 was well
tolerated at all dose levels through 6 months of follow-up.
Clinical Trials Registration. NCT01891331.
Keywords. acute vulvovaginal candidiasis; randomized clinical study; VT-1161.

Assessed for eligibility (n = 69)
Excluded (n = 14)
• Not meeting inclusion criteria (n = 14)
Randomized (N = 55)

Allocation

VT-1161 600 mg q.d.
(n = 12)

VT-1161 600 mg b.i.d.a
(n = 14)

Fluconazole 150 mg
(n = 15)

Follow-up

Terminated prematurely
• AE (n = 0)
• Lost to follow-up (n = 2)
• Other (n = 0)

Terminated prematurely
• AE (n = 0)
• Lost to follow-up (n = 1)
• Other (n = 1)

Terminated prematurely
• AE (n = 0)
• Lost to follow-up (n = 1)
• Other (n = 0)

Terminated prematurely
• AE (n = 0)
• Lost to follow-up (n = 2)
• Other (n = 0)

Analysis

VT-1161 300 mg q.d.
• ITT population (n = 14)
• mITT population (n = 11)
• PP population (n = 8)
• Safety population (n = 14)

VT-1161 600 mg q.d.
• ITT population (n = 12)
• mITT population (n = 8)
• PP population (n = 7)
• Safety population (n = 12)

VT-1161 600 mg b.i.d.
• ITT population (n = 14)
• mITT population (n = 14)
• PP population (n = 14)
• Safety population (n = 14)

Fluconazole 150 mg
• ITT population (n = 15)
• mITT population (n = 9)
• PP population (n = 8)
• Safety population (n = 15)

Figure 1. Flow diagram of participant disposition. aAfter all participants in the 2 lower VT-1161 dose regimens completed their test-of-cure visit (day 28), an interim analysis was conducted to determine randomization into the VT-1161 600 mg b.i.d. group. Abbreviations: AE, adverse event; b.i.d., twice daily; ITT, intent-to-treat; mITT, modified
intent-to-treat; PP, per-protocol; q.d., once daily; VT-1161, oteseconazole.

(mid dose), or VT-1161 600 mg twice daily (b.i.d.) for 3 days
(high dose) or fluconazole 150 mg administered orally in a
single dose (administered blinded to match the VT-1161 dose
regimens).
An interactive web response system was used to initially randomize participants in a 3:3:2 ratio to 300 mg q.d. or 600 mg
q.d. VT-1161 or fluconazole. Participants were stratified by
composite vulvovaginal signs and symptoms severity score (6–8
and ≥9) at screening and monitored to ensure that ≥50% of the
participants had a VVC severity score of ≥9.
An interim safety analysis was performed after all participants
randomized to receive VT-1161 300 mg q.d. and 600 mg q.d.
(first randomization) had completed their test-of-cure (TOC)
visit on day 28. Demographics and baseline characteristics, adverse events (AEs), laboratory assessments, electrocardiograms

(ECGs), and efficacy. PK data were summarized and reviewed
by the independent medical monitor. Based on this analysis, the
VT-1161 600 mg b.i.d. group was added. After the interim analysis, participants were randomized in a 3:1 ratio to 600 mg b.i.d.
VT-1161 or fluconazole. A second interim analysis was performed to review safety, efficacy, and PK when the last participant of the VT-1161 600 mg b.i.d. group completed their TOC
visit. The duration of individual participant participation was
approximately 6 months.
Participants returned to the clinic on days 7, 14, 28, 84
(3 months), and 168 (6 months) for efficacy, safety, laboratory,
and PK assessments. TOC was assessed on day 28.
The trial was conducted in accordance with the Declaration
of Helsinki and the Guidelines for Good Clinical Practice. The
study protocol was reviewed and approved by the appropriate
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VT-1161 300 mg q.d.
(n = 14)

institutional review board. All participants gave written informed consent before participating in the study.
Study Population

Outcomes

Efficacy measurements included collection of clinical signs (erythema, edema, excoriation) and symptoms (itching, burning,
irritation) of vulvovaginitis using a scoring scale of 0–3
(0 = none, 1 = mild, 2 = moderate, 3 = severe) for each sign or
symptom to give a total severity score of 0–18 [11]. In addition, a KOH wet mount test and vaginal fungal culture were
performed at each visit.
The primary efficacy outcome was the proportion of participants with therapeutic cure, defined as both clinical and mycological cure, at the TOC day 28 visit. Mycological cure was
defined as a negative fungal culture for Candida species. Clinical
cure was defined as follows: complete resolution of signs and
symptoms pertaining to VVC and any new sign or symptom
observed at the TOC visit determined by the investigator not to
be related to VVC.
The secondary efficacy outcome measures were the proportion of participants with the following: clinical cure at day 28;
mycological cure at days 7, 14, and 28; clinical improvement
(every individual VVC signs and symptoms score that was 0,
1, or 2 at baseline was a score of 0 at day 28, and scores of 3 at
baseline were scores of 0 or 1 at day 28); clinical relapse (clinical cure at day 28 and signs and symptoms total severity score
>0 at day 84 or day 168); mycological reinfection or recurrence
(negative fungal culture at day 28 and positive fungal culture
for Candida species at day 84 or day 168); modified clinical cure
e1520 • cid 2021:73 (1 October) • Brand et al

Determination of Minimum Inhibitory Concentration

The minimum inhibitory concentration (MIC) of VT-1161
and fluconazole against each clinical isolate was determined
according to Clinical and Laboratory Standards Institute M27A3 [12]. Briefly, 1640 Roswell Park Memorial Institute medium
was inoculated and incubated at 35ºC for 24 hours. The MIC
end points were recorded at 50% inhibition as compared to the
growth control.
Statistical Analyses

A sample size of 12 participants per treatment group was based
on clinical judgment; no formal power calculations were performed. Treatment differences were compared using the
Cochran–Mantel–Haenszel test. All tests were 2-sided, and inferential analyses used an alpha level of 0.05. All statistical analyses were conducted using SAS version 9.2.
AEs were coded using the Medical Dictionary for Regulatory
Activities (MedDRA), version 16.0. The number and percentage
of participants who had treatment-emergent AEs (TEAEs) were
tabulated by system organ class and MedDRA preferred term
with a breakdown by treatment group. Mean changes from pretreatment in vital signs, ECGs, and clinical laboratory variables
were summarized by treatment group.
The following PK parameters were derived from the plasma
concentration vs time data from participants who underwent
serial PK sampling after dosing on day 1: maximum measured
plasma concentration (Cmax), area under the plasma concentration vs time curve (AUC), and time to Cmax (tmax).
Three analysis populations were defined as follows: the perprotocol (PP) population included all randomized participants who met all inclusion/exclusion criteria, had a positive
baseline vaginal fungal culture Candida species, received all
doses of study drug, were compliant with the assigned study
treatment, completed the TOC visit within an acceptable

Downloaded from https://academic.oup.com/cid/article/73/7/e1518/5895051 by guest on 15 November 2021

Healthy, nonpregnant female participants aged ≥18 years and
<65 years with a clinical diagnosis of symptomatic acute VVC
were enrolled in the study. Participants had a positive baseline potassium hydroxide (KOH) wet mount from a vaginal
smear revealing filamentous hyphae/pseudohyphae or budding yeast cells, presence of ≥1 vulvovaginal sign, presence of
≥1 vulvovaginal symptom, and a composite severity score of
≥6. Vaginal swabs were obtained at the screening visit and at
subsequent study visits. Candida species were characterized
and stored frozen for susceptibility testing at study completion.
Inclusion criteria required participants to present with a clinical
diagnosis of acute VVC and did not differentiate between acute
and recurrent VVC participants.
Participants did not have any clinically significant major
organ system disease or infection (with the exception of VVC)
and were not taking concomitant medications that would have
interfered with study assessments.
Participants completed a review of pertinent medical history,
vital signs, and body measurements; a symptom/sign evaluation; a physical examination including speculum examination
of the vagina; and a KOH wet mount test from a vaginal smear.

(total VVC severity score of ≤1 at day 28); modified therapeutic
cure (modified clinical cure and mycological cure at day 28);
and therapeutic improvement (clinical improvement and mycological cure at day 28). Additional evaluations included the
following: number of participants with a change in clinical signs
and symptoms from baseline to day 28; number of participants
with positive culture and KOH test at days 28, 84, and 168; and
PK analyses.
PK samples were obtained from all participants prior to
dosing of the study drug on day 1 and at each subsequent visit.
Serial sampling was obtained from consenting participants at
participating sites on day 1 (pre-dose and 1, 2, 3, 4, 5, 6, and
8 hours after dosing).
AEs were collected throughout the study. Physical examination findings, vital signs, ECGs, and safety laboratory tests (hematology, chemistry, and urinalysis) were recorded at baseline
and throughout the study.

time window, had no major protocol violations, and had not
received another systemic antifungal drug that has documented activity against the causative organism while on
study before the TOC assessment, unless the participant had
a therapeutic response of failure. The intent-to-treat (ITT)/
safety population included all randomized participants who
received ≥1 dose of study drug. The modified ITT (mITT)
population included all randomized participants who met
the inclusion/exclusion criteria, had a positive baseline vaginal fungal culture for Candida species, received ≥1 dose of
study drug, and returned for ≥1 postbaseline visit.

Participant Demographics and Disposition

Between October 2013 and September 2014, 55 female
participants were randomized into the study (Figure 1).
Participants were followed for approximately 6 months including up to 3 days for screening, 3 days for study drug
administration, and a final follow-up visit 6 months after
starting treatment.
The study had a high rate of completion across all groups:
VT-1161 300 mg q.d., 12/14, 85.7%; VT-1161 600 mg q.d.,
10/12, 83.3%; VT-1161 600 mg b.i.d., 13/14, 92.9%; and
fluconazole 150 mg single dose, 13/15, 86.7%. No participant
withdrew from the study due to an AE. All protocol deviations
were considered to be minor and did not affect study outcomes.
Baseline participant demographics are summarized in
Table 1. Overall, the average age of participants was 32.7 years.
Baseline characteristics were similar across the groups.
Efficacy

The primary efficacy outcome was the proportion of participants with therapeutic cure at the day 28 TOC visit. These
data are summarized for all populations (PP, mITT, and
ITT) in Table 2. A larger proportion of participants in the
Table 1.

Participant Demographics and Baseline Characteristics
VT-1161 300 mg q.d.
(n = 14)

VT-1161 600 mg q.d.
(n = 12)

VT-1161 600 mg b.i.d.
(n = 14)

Fluconazole 150 mg
(n = 15)

Overall (N = 55)

34.4 ± 12.01

38.2 ± 11.77

27.6 ± 7.37

31.3 ± 8.22

32.7 ± 10.40

White

7 (50.0)

9 (75.0)

4 (28.6)

9 (60.0)

29 (52.7)

Black

7 (50.0)

3 (25.0)

9 (64.3)

6 (40.0)

25 (45.5)

Asian

0

0

1 (7.1)

0

1 (1.8)

Parameter
Age (y)
Race

Ethnicity
Hispanic or Latino

1 (7.1)

4 (33.3)

1 (7.1)

3 (20.0)

9 (16.4)

13 (92.9)

8 (66.7)

13 (92.9)

12 (80.0)

46 (83.6)

Height (cm)

162.4 ± 4.46

159.3 ± 5.89

162.9 ± 4.42

160.5 ± 5.80

161.3 ± 5.23

Weight (kg)

72.2 ± 16.55

72.6 ± 17.35

71.4 ± 20.70

73.9 ± 14.49

72.6 ± 16.90

27.3 ± 5.52

28.7 ± 7.06

26.9 ± 7.63

28.7 ± 5.22

27.9 ± 6.27

Not Hispanic or Latino

Body mass index (kg/
m2)

Data are mean ± standard deviation or n (%).
Abbreviation: b.i.d., twice daily; q.d., once daily; VT-1161, oteseconazole.

Acute Vulvovaginal Candidiasis Treatment • cid 2021:73 (1 October) • e1521

Downloaded from https://academic.oup.com/cid/article/73/7/e1518/5895051 by guest on 15 November 2021

RESULTS

PP population experienced therapeutic cure in the VT-1161
300 mg q.d. (6/8, 75.0%), VT-1161 600 mg q.d. (6/7, 85.7%),
and VT-1161 600 mg b.i.d. (11/14, 78.6%) treatment groups vs
the fluconazole 150 mg group (5/8, 62.5%). No statistically significant difference was observed for any of the VT-1161 treatment groups vs the fluconazole group. The secondary efficacy
outcome measures included the proportion of participants with
clinical cure, mycological cure, clinical improvement, clinical
relapse, and mycological relapse. These data are summarized
for the PP population in Table 3.
At day 28, a larger proportion of participants in the PP population experienced clinical cure, mycological cure, clinical
improvement, and no clinical or mycological relapse in the
3 VT-1161 treatment groups vs the fluconazole group. At day
28, a larger proportion of participants in the PP population experienced modified therapeutic cure in the 3 VT-1161 treatment groups vs the fluconazole group (Figure 2).
All participants treated with VT-1161 demonstrated mycological cure at both the day 84 (3-month) and day 168
(6-month) follow-up visits, while almost half of the participants treated with fluconazole showed a mycological recurrence at the 6-month visit. The percentage of participants in the
fluconazole-treated group who experienced mycological recurrence increased with time since treatment.
Additional efficacy analyses included the number of participants with a positive culture for Candida species and KOH
test evaluated at days 28, 84, and 168 (Table 4). All participants
treated with VT-1161 demonstrated mycological cure at both
the day 84 (3-month) and day 168 (6-month) follow-up visits,
while almost half of the participants treated with fluconazole
showed a mycological recurrence at the 6-month visit.
At screening, 41 isolated cultures (89%) were Candida
albicans, 9 isolated cultures (7%) were Candida parapsilosis,
1 culture (2%) was Candida tropicalis, and 1 culture (2%)
was Candida lusitanea. Candida glabrata was isolated from a

Table 2.

Percentage of Participants With Therapeutic Cure at Test-of-Cure Visit Day 28

Population
Per-protocol
Yes
No
95% CI
P valuea
Modified intent-to-treat
Yes
No
95% CI

VT-1161 300 mg q.d., n (%)

VT-1161 600 mg q.d., n (%)

VT-1161 600 mg b.i.d., n (%)

n=8

n=7

n = 14

Fluconazole 150 mg, n (%)
n=8

6 (75.0)

6 (85.7)

11 (78.6)

5 (62.5)

2 (25.0)

1 (14.3)

3 (21.4)

3 (37.5)

34.9–96.8

42.1–99.6

49.2–95.3

24.5–91.5

.956

.371

.363

n = 11

n=8

n = 14

n=9

7 (63.6)

6 (75.0)

11 (78.6)

6 (66.7)

4 (36.4)

2 (25.0)

3 (21.4)

3 (33.3)

30.8–89.1

34.9–96.8

49.2–95.3

29.9–92.5

.691

.657

.506

Intent-to-treat

n = 14

n = 12

n = 14

n = 15

9 (64.3)

9 (75.0)

11 (78.6)

10 (66.7)

Yes
No

5 (35.7)

3 (25.0)

3 (21.4)

5 (33.3)

95% CI

35.1–87.2

42.8–94.5

49.2–95.3

38.4–88.2

P valuea

.521

.496

.296

Abbreviation: b.i.d., twice daily; CI, confidence interval; q.d., once daily; VT-1161, oteseconazole.
a
P values are from Cochran–Mantel–Haenszel tests comparing each VT-1161 treatment group to fluconazole, stratified by baseline composite vulvovaginal signs and symptoms severity
score (6–8 and ≥9).

Table 3.

Secondary Outcome Results for Per-Protocol Population

Secondary Outcome
Clinical cure (day 28)
Yes
No
95% CI
P valuea
Mycological cure (day 7)
Yes
No
95% CI
P valuea
Mycological cure (day 14)
Yes
No
95% CI
P valuea
Mycological cure (day 28)
Yes
No
95% CI
P valuea
Clinical improvement (day 28)
Yes
No
95% CI
P valuea

VT-1161 300 mg q.d., n (%)

VT-1161 600 mg q.d., n (%)

VT-1161 600 mg b.i.d., n (%)

Fluconazole 150 mg, n (%)

n=8

n=7

n = 14

n=8

6 (75.0)

7 (100.0)

12 (85.7)

5 (62.5)

2 (25.0)

0

2 (14.3)

3 (37.5)

34.9–96.8

59.0–100.0

57.2–98.2

24.5–91.5

.956

.109

.182

n=8

n=7

n = 14

n=8

8 (100.0)

6 (85.7)

14 (100.0)

8 (100.0)

0

1 (14.3)

0

0

63.1–100.0

42.1–99.6

76.8–100.0

63.1–100.0

–

.414

–

n=8

n=7

n = 14

n=8

8 (100.0)

6 (85.7)

14 (100.0)

5 (62.5)

0

1 (14.3)

0

3 (37.5)

63.1–100.0

42.1–99.6

76.8–100.0

24.5–91.5

.073

.260

.021

n=8

n=7

n = 14

n=8

8 (100.0)

6 (85.7)

13 (92.9)

6 (75.0)

0

1 (14.3)

1 (7.1)

2 (25.0)

63.1–100.0

42.1–99.6

66.1–99.8

34.9–96.8

.285

.624

.224

n=8

n=7

n = 14

n=8

7 (87.5)

7 (100.0)

12 (85.7)

6 (75.0)

1 (12.5)

0

2 (14.3)

2 (25.0)

47.3–99.7

59.0–100.0

57.2–98.2

34.9–96.8

.621

.221

.495

n=6

n=7

n = 12

n=5

Yes

1 (16.7)

0

1 (8.3)

1 (20.0)

No

5 (83.3)

7 (100)

11 (91.7)

4 (80.0)

n=8

n=6

n = 13

n=6

Yes

0

2 (33.3)

0

4 (66.7)

No

8 (100.0)

4 (66.7)

13 (100.0)

2 (33.3)

Clinical relapseb

Mycological relapsec

Abbreviation: b.i.d., twice daily; CI, confidence interval; q.d., once daily; VT-1161, oteseconazole.
a

P values are from Cochran–Mantel–Haenszel tests comparing each VT-1161 treatment group to fluconazole.

b

n is the number of participants who experienced clinical cure at day 28.

c

n is the number of participants who experienced mycological cure at day 28.
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P valuea

100
90

87.5%
(7/8)

85.7%
(6/7)

85.7%
(12/14)

Patients with modified
therapeutic cure (%)

80

VT-1161 concentrations on day 168 remained measurable
(127, 409, and 1300 ng/mL for the 300 mg q.d., 600 mg q.d., and
600 mg b.i.d. treatment groups, respectively). Median half-lives
for the current study were calculated as 76 days for the low dose
to 160 days for the high dose cohort.

75.0%
(6/8)

70
60
50
40
30

Safety

20
10
0

Low-dose VT-1161
300 mg q.d. × 3 days

Mid-dose VT-1161
600 mg q.d. × 3 days

High-dose VT-1161
600 mg b.i.d. × 3 days

Fluconazole
150 mg q.d. × 1 day
(per label)

single participant while on-study. Based on the MIC susceptibility results, VT-1161 was shown to have potent activity
against the Candida strains obtained in the study. When all
60 Candida spp. isolates collected throughout the study were
considered, the MIC ranges for VT-1161 and fluconazole were
<0.001–1.0 and <0.125–64 µg/mL, respectively. The MIC50
(defined as the minimum concentration to inhibit 50% of the
strains tested) was 0.002 µg/mL for VT-1161 and 0.25 µg/mL
for fluconazole, whereas the MIC90 (defined as the minimum
concentration to inhibit 90% of the strains tested) was 0.004 µg/
mL for VT-1161 and 1.0 µg/mL for fluconazole. Overall, the
VT-1161 MIC values were approximately 100-fold lower than
those of fluconazole. Importantly, the MIC of VT-1161 against
the fluconazole-resistant C. glabrata was 64-fold lower than the
fluconazole MIC.
Pharmacokinetics

The median tmax of VT-1161 was 4.0 hours (range, 3.1–5.0) and
5.5 hours (range, 4.0–8.0) for the 300- and 600-mg doses, respectively. On day 1, Cmax was 407 ng/mL for the 300-mg dose
and 968 ng/mL for the 600-mg dose. The AUC(0–8) values on
day 1 averaged 1870 and 4230 hours × ng/mL for the 300- and
600-mg doses, respectively.

Table 4. Number of Participants With Positive Culture and Potassium
Hydroxide Test During Follow-up for Intent-to-Treat Population
(Mycological Recurrence)

Visit

VT-1161 300
VT-1161 600
mg q.d., n/N (%) mg q.d., n/N (%)

VT-1161 600
mg b.i.d., n/N
(%)

Fluconazole
150 mg, n/N
(%)

Day 28

0/14 (0)

1/12 (8.3)

0/14 (0)

2/14 (14.3)

Day 84

0/14 (0)

0/11 (0)

0/14 (0)

4/14 (28.6)

Day 168

0/12 (0)

0/11 (0)

0/13 (0)

6/13 (46.1)

Abbreviation: b.i.d., twice daily; CI, confidence interval; q.d., once daily; VT-1161,
oteseconazole.

DISCUSSION

The primary efficacy outcome, therapeutic cure at day 28, was
observed in the majority of participants across all treatment
groups. Secondary outcome analyses showed similar results as
the primary efficacy outcome. Generally, there was no statistical difference between VT-1161 and fluconazole treatment
groups; however, the study was not prospectively powered for
the primary end point, and sample sizes were small. While the
current preliminary study did not differentiate between acute
or recurrent VVC participants, requiring only an acute episode at presentation, analyses at the 3-month and 6-month
follow-up visits found no indication of mycological recurrence
in the VT-1161 groups, while 29% and 46% of participants in
the fluconazole group had mycological recurrence at 3 and
6 months, respectively. During the 6-month trial, a higher percentage of fluconazole-treated participants reported TEAEs
than VT-1161–treated participants.
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Figure 2. Modified therapeutic cure of VT-1161 dose regimens vs fluconazole
for acute vulvovaginal candidiasis (day 28) in the per-protocol population. Note:
Modified therapeutic cure = total VVC signs and symptoms severity score of ≤1
and mycological cure at day 28. Abbreviations: b.i.d., twice daily; q.d., once daily;
VT-1161, oteseconazole.

A total of 19 TEAEs were reported in the participant group
that received 300 mg q.d. VT-1161 (n = 14); 17 TEAEs were
reported in the participant group that received 600 mg q.d.
VT-1161 (n = 12); 4 TEAEs were reported in the participant
group that received 600 mg b.i.d. VT-1161 (n = 14), and 22
TEAEs were reported in the participant group that received
fluconazole.
The most common TEAEs were in the infections and infestations system organ class (16 participants, 29.1%), including the
preferred terms nasopharyngitis, urinary tract infection, and
vaginitis bacterial, which were reported across all treatment
groups. Most TEAEs were mild or moderate in intensity and
resolved during the study. A total of 7 participants (12.7%) reported 15 treatment-related TEAEs: 3 participants each in the
300 mg q.d. and 600 mg q.d. VT-1161 treatment groups and
1 participant in the fluconazole treatment group. Three participants reported treatment-related events of nausea: 1 participant in the VT-1161 300 mg q.d. group and 2 participants
in the VT-1161 600 mg q.d. group. All other TEAEs were reported for only 1 participant each. No serious AEs, deaths, or
TEAEs leading to study discontinuation were reported. Two
pregnancies were reported during the study for participants in
the fluconazole treatment group, which resulted in a full-term
infant and a miscarriage. There were no clinically significant
treatment-emergent changes in vital signs, physical findings,
ECGs, or laboratory parameters.
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Currently, women with uncomplicated acute VVC are treated
with single-dose or short-course treatments; those with complicated, resistant, or recurring VVC (up to 20% of women) require therapy for ≥5–7 days and possibly maintenance therapy
[13]. Topical agents are limited by local side effects, especially
burning, and are messy to apply; therefore, most women prefer
oral regimens. Systemically administered available azoles, such as
fluconazole, can exhibit toxicity and DDI issues [3, 4] and come
with reproductive warnings [14]. Furthermore, resistance surveillance studies have found that current azole therapies can have poor
activity against C. glabrata [15, 16], and cross-resistance among
current azole antifungal agents has been observed [17].
In a previous study that compared a 6-month weekly maintenance fluconazole regimen to placebo in patients with recurrent VVC, the percentage of fluconazole-treated patients who
had a recurrence (defined as a clinical severity score of ≥3 and
vaginal culture positive for yeast) at the 6-month end of maintenance phase visit was 9%. At the 9-month and 12-month observation phase visits, this percentage increased to 27% and 57%,
respectively [2]. This trend of increasing recurrence rates in the
6 months following fluconazole treatment is similar to the mycological recurrence rates observed in fluconazole-treated participants in this trial and highlights the unmet medical need
for these patients. We have previously reported the potential
clinical utility of VT-1161 in women with recurrent VVC [18].
Overall, recurrence rates of culture-proven VVC were only
4% in the 169 VT-1161–treated participants at 9 months after
ending the study drug compared with 52% in the 46 women
who received placebo. Our current study shows that VT-1161
may also be an effective treatment for acute VVC.
During this trial, VT-1161 was safe and well tolerated at all
dose levels through 6 months of follow-up. As an initial phase
2 study with a small number of participants, its main limitation
was that it was not powered to permit meaningful comparisons
between different treatment groups. Nevertheless, our findings
suggest that VT-1161 is worthy of further investigation for both
acute and recurrent VVC.

